NCT06411678View on ClinicalTrials.gov

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Breast Cancer
Interventions
DRUG

68GA-DOTA-dPNE

Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection

Trial Locations (1)

100730

RECRUITING

PUMCH, Dongcheng

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER